Medical Affairs Reputations Non-small Cell Lung Cancer EU5 - New Study Released

From: Fast Market Research, Inc.
Published: Wed Jun 08 2016


Four medical affairs teams battling it out for top spot. How does your team compare?

In the fiercely competitive European non-small cell lung cancer (NSCLC) treatment market, one medical affairs team leads. But for how long? With three other brands close behind, and high satisfaction scores for all brands across the board, it isn't easy to stand out from the competition.

Where does that leave your team?

Are you giving oncologists the services they want most? Are you available when and where they need you? What can you do to boost your team's performance, and differentiate your team?

Get the report and find out.

Not your market? Click here to see the US report

Reasons to Get this Report

Answering Key Questions about Medical Affairs Teams for 8 Major NSCLC Brands

* Avastin (bevacizumab; Roche): Which other brand's team is tied with Avastin's for overall quality of interactions?
* Giotrif (afatinib; Boehringer Ingelheim): What's the one area where Giotrif's team scores significantly better than the leading brand's team?
* Iressa (gefitinib; AstraZeneca): Which team has higher overall quality scores, Iressa's or Xalkori's?
* Keytruda (pembrolizumab;Merck Sharpe & Dohme. ): Keytruda's team gets the lowest satisfaction score in one important area. Which one?
* Opdivo (nivolumab; Bristol-Myers Squibb): Do oncologists feel that Opdivo's medical affairs team responds more quickly to medical inquiries than Giotrif, or Keytruda's teams?
* Tarceva (erlotinib; Roche): Is Tarceva's medical affairs team more active than Xalkori's or Avastin's?
* Xalkori (crizotinib; Pfizer/Merck): Xalkori's team's performance is tied with the two leading teams' in one important area. Which one?
* Zykadia (ceritinib; Novartis): Z ykadia's team gets the top performance score in four areas. Which ones?

Full Report Details at
- http://www.fastmr.com/prod/1180397_medical_affairs_reputations.aspx?afid=301

Top Takeaways

* Competition is fierce: Rated for overall quality of interactions, the top four teams are no more than two points apart, and two of them are tied for third place.
* Hard for teams to stand out: Performance scores in every area-and satisfaction scores in most areas-are very close across brands.
* Solid performance, but not perfect: Every team is doing well in areas oncologists consider important, but all of them still have specific improvements to make.
* Little interest in digital interactions: Fewer than half of oncologists surveyed prefer email communications. Even fewer prefer other digital interactions.
* "Attitude" adjustment needed: Despite high overall satisfaction, oncologists say teams can stand to improve their medical affairs attitude and practice in three specific ways.
* Teams more active in EU than in US: European teams are highly active, and tend to have more interactions with oncologists that their US counterparts. Get the US report for details.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Medical Affairs Reputations Non-small Cell Lung Cancer US
- Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
- Medical Affairs Reputations: Renal Cell Carcinoma (US)
- Global Non-Small Cell Lung Cancer Therapeutics Market 2015-2019
- Market Access Impact: Renal Cell Carcinoma (EU5)

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »